<DOC>
	<DOCNO>NCT01449266</DOCNO>
	<brief_summary>To evaluate dialysability Dotarem® , IV injection 0.1 mmol/kg patient chronic renal failure require hemodialysis treatment .</brief_summary>
	<brief_title>Safety Dialysability Dotarem® Dialysed Patients</brief_title>
	<detailed_description>Ten adult patient suffer end stage renal failure require hemodialysis treatment 3 time enrol . Patients receive single dose Dotarem® 0.1 mmol/kg submit hemodialysis ass dialysability Dotarem® . After injection Dotarem® , 3 session hemodialysis perform follow : The first hemodialysis session start 1 2 h injection ; The second hemodialysis session occur 2 day ( i.e. , 48 ± 2 h ) Dotarem® injection ; The third hemodialysis session occur 4 day ( i.e. , 96 ± 4 h ) Dotarem® injection . The decrease serum Dotarem® concentration assess hemodialysis session . Safety assessment include adverse event ( AEs ) , vital sign , injection-site tolerance , laboratory assessments.Two safety follow-up visit perform : one 3 week ( ± 2 day ) one 3 month ( ± 4 day ) Dotarem® injection .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Male female , age ≥18 year Subjects suffer endstage renal failure require hemodialysis treatment 3 time per week ( equivalent allow overnight dialysis reschedule appropriate per protocol ) Female Subjects effective contraception ( contraceptive pill IntraUterine Device ) , surgically sterilize postmenopausal ( minimum 12 month amenorrhea ) Subjects provide write informed consent participate trial Known allergy gadolinium chelate Pregnant , breast feeding , plan become pregnant trial Having receive schedule inject contrast agent within 7 day Dotarem® injection Schedule receive erythropoietin ( EPO ) iron therapy 1 week Dotarem® injection Evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Evidence hepatitis C and/or positive hepatitis C antibody and/or positive hepatitis B surface antigen History hypersensitivity drug similar chemical structure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Dotarem</keyword>
	<keyword>Dialyses</keyword>
	<keyword>Dialysed</keyword>
	<keyword>Safety</keyword>
	<keyword>Safety dialysability Dotarem dialyse patient</keyword>
</DOC>